Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Epidemiology and Clinical Characteristics of Meningitis Following COVID-19 Vaccinations: A Systematic Review
Infectious Disease
P9 - Poster Session 9 (8:00 AM-9:00 AM)
Vaccines are crucial in combating infectious disease outbreaks, including coronavirus disease
2019 (COVID-19). Global efforts led to the rapid development and widespread administration of COVID-19 vaccines. Despite rare adverse events, such as Guillain–Barré syndrome, myelitis, and encephalitis, cases of COVID-19 vaccine-related meningitis are infrequent.
We conducted the current study to provide a comprehensive overview of the current evidence on the occurrence, classifications, clinical characteristics, management, and prognosis of meningitis following COVID-19 vaccination.

We systematically searched PubMed, Scopus, and Web of Science until March 2023 for studies on meningitis following COVID-19 vaccinations. Two reviewers screened the studies independently, resolving discrepancies with a third reviewer. We extracted data on patient demographics (age and gender), COVID-19 vaccine type and dosage, meningitis occurrence, time between vaccination and symptom onset, meningitis-related neurological and non-neurological symptoms, cerebrospinal fluid analysis, relevant lab and imaging results, diagnosis, and treatment outcomes.

This review included 26 records involving 31 patients. The mean patient age was 44.29 ± 19.48 years, with 18 females and 13 males. Aseptic meningitis was seen in 45.2% of cases, varicella-zoster virus (VZV) meningitis in 38.7%, aseptic meningoencephalitis in 9.7%, and Myelin oligodendrocyte glycoprotein antibody-associated disease meningitis in two patients. Meningitis occurred more frequently after BNT162b2 vaccination (67.7%), followed by ChAdOx1 nCoV-19 vaccine (22.6%), Sinovac inactivated vaccine, and m-RNA 1273 vaccine. However, there was no statistically significant association between the type of COVID-19 vaccine and the type of meningitis (p= 0.197). Neurological symptoms were reported in 22 and 7 patients after the first and second vaccine doses, respectively.

Aseptic meningitis (45.2%) and VZV meningitis (38.7%) were the most prevalent types of meningitis  following COVID-19 vaccines. Of note, the benefits of vaccination with these vaccines still outweigh the risks. Efforts to develop better vaccines with limited adverse effects and the capacity to prevent transmission must continue.

Mostafa M. Meshref, MD (Al-Azhar University, Cairo)
Dr. Meshref has nothing to disclose.
Mohamed S. Shehata, MBBS (Nasr City Insurance Hospital) Dr. Shehata has nothing to disclose.
Amany Mahfouz No disclosure on file
Hossam T. Ali, MD (Qena Faculty of Medicine) Dr. Ali has nothing to disclose.
Abdelmonem Siddiq No disclosure on file
Aya Al Mawla No disclosure on file